Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

3.820 -0.080 (-2.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Clene Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Blood Test Could Detect Worsening MS Symptoms in Patients
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Q3 2023 Financial Results, Operating Highlights
Via Investor Brand Network
Australian Study Finds Way to Detect Parkinson’s Prior to Symptom Onset
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Four-Year Grant to Support Expanded Access Protocol for CNM-Au8 From NINDS
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) ‘Innovates’ Investigational Drug with Patented Nanotechnology
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Applies Patented Nanotechnology to Development of CNM-Au8(R), its Investigational Drug for ALS
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Featured in Latest Episode of The Bell2Bell Podcast
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Releases Significant Long-Term Survival Improvement Data from ALS Trial
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $40M Public Offering
Via Investor Brand Network
Clene: Still in the Running for ALS
New York, New York, United States - 02-14-2023 (PR Distribution™) - 
Via PR Distribution
Topics Death
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
From Clene Inc.
Via GlobeNewswire
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
From Clene Inc.
Via GlobeNewswire
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
From Clene Inc.
Via GlobeNewswire
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
Funding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor Hogan 
From Clene Inc.
Via GlobeNewswire
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
From Clene Inc.
Via GlobeNewswire
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
From Clene Inc.
Via GlobeNewswire
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
From Clene Inc.
Via GlobeNewswire
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
From Clene Inc.
Via GlobeNewswire
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
Conference Call and Webcast Set for 8:30 a.m. EDT 
From Clene Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.